[VIRTUAL] Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

[VIRTUAL] Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data

[VIRTUAL] KEYNOTE 629: Phase 2 study of pembrolizumab monotherapy for locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma

[VIRTUAL] Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or are intolerant to hedgehog inhibitors

[VIRTUAL] Primary analysis of Phase 2 results for cemiplimab in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors

[VIRTUAL] Analysis of efficacy outcomes using ERIVANCE-like methodology in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg

[VIRTUAL] Two patients treated with Hedgehog inhibitor (HHI) and anti-PD-1 antibody for concomitant diagnosis of advanced Basal Cell Carcinoma (aBCC) and cutaneous Squamous Cell Carcinoma (cSCC)

[VIRTUAL] A Phase II study of intralesional Daromun (L19IL2 + L19TNF) in non-melanoma skin cancer patients with localized disease (NCT04362722)

[VIRTUAL] Phase II trial evaluating Resminostat for maintenance treatment of patients with advanced stage (Stage IIB‑IVB) mycosis fungoides (MF) or Sézary syndrome (SS) – RESMAIN study

[VIRTUAL] Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study

[VIRTUAL] PIVOT-12: a Phase 3 randomized study of adjuvant bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) versus NIVO in completely resected cutaneous melanoma at high risk for recurrence

[VIRTUAL] KEYMAKER-U02: Phase 1/2 study of investigational agents with or without pembrolizumab or pembrolizumab alone in patients with melanoma

[VIRTUAL] First-line CMP-001 plus nivolumab vs nivolumab alone in a randomized, open-label, phase 2/3 study (CMP-001-011) in patients with unresectable or metastatic melanoma

[VIRTUAL] Nemvaleukin alfa monotherapy in patients with advanced melanoma: ARTISTRY-1

[VIRTUAL] Phase I trial: personalized vaccination with IKKb-matured, RNA-loaded dendritic cells for metastatic uveal melanoma